More than a fifth of community pharmacies have cut opening hours in one year Exclusive: The most common drop in opening hours was between 2 and 4 hours per week, with some pharmacies reducing hours by more than 32 hours per week.…
Paul Rees: ‘Pharmacy First could be the saviour of general practice’ The National Pharmacy Association’s new chief executive sets out what needs to change to address the ‘urgent crisis’ unfolding in community pharmacy.…
RPS consults on advanced curricula for critical care and mental health pharmacy Once finalised, the two new curricula will be add-on modules to the Royal Pharmaceutical Society's core advanced pharmacist curriculum, published in June 2022.…
Three core values of community pharmacy are fundamental to a healthy future How the community pharmacy network offers a unique combination of values to patients and the public that must be capitalised on.…
Pharmacy regulator consults on draft standards for chief pharmacists By producing new standards, the General Pharmaceutical Council says its aim is to clarify chief pharmacists’ roles and responsibilities to improve pharmacy governance.…
No progress on post-Brexit falsified medicines scheme in UK Health minister Andrew Stephenson said the Department of Health and Social Care was still “considering the right approach for the future”.…
The vision for supervision As 2023 draws to a close, our health policy columnist says pharmacy could be the solution to alleviating workforce issues that continue to plague the NHS.…
All emergency departments must have dedicated pharmacist, royal college and UKCPA say The joint statement also says that there should be one whole-time equivalent pharmacist for every ten resuscitation beds in an emergency department.…
How has 2023 stacked up for the pharmacy sector? From pharmacy closures to Pharmacy First, 2023 has laid the foundations for a game-changing 2024. Here, we take a look back at the biggest headlines of the year.…
PJ view: Transparency in the science behind government policy is vital Questions have been raised about whether the government was right to rush a deal to provide inclisiran on the NHS without data to substantiate claims about its effectiveness.…
